Real-world effectiveness of brentuximab vedotin vs other treatments in patients with relapsed/refractory hodgkin lymphoma post autologous stem-cell transplantation.
Authors
Zagadailov, ECorman, S
Hagan, M
Chirikov, V
Johnson, C
Macahilig, C
Sea, B
Dalal, M
Brockelmann, P
Illidge, Timothy M
Affiliation
Millennium Pharmaceuticals, Inc., Cambridge, MA, USAIssue Date
2017-05-24